Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 14Recruiting 8Active not recruiting 5Unknown 4Terminated 3Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 5

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 705Carcinoma, Non-Small-Cell Lung 472Prostatic Neoplasms 420Neoplasms 379Multiple Myeloma 261Colorectal Neoplasms 261Lung Neoplasms 248Neoplasm Metastasis 230Melanoma 215Ovarian Neoplasms 191Leukemia, Myeloid, Acute 190Pancreatic Neoplasms 181Squamous Cell Carcinoma of Head and Neck 163Recurrence 146Carcinoma, Renal Cell 144Lymphoma 142Glioblastoma 138Lymphoma, Non-Hodgkin 134Stomach Neoplasms 129Triple Negative Breast Neoplasms 127Carcinoma, Hepatocellular 123Brain Neoplasms 123Leukemia, Lymphocytic, Chronic, B-Cell 122Uterine Cervical Neoplasms 117Head and Neck Neoplasms 117Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Urinary Bladder Neoplasms 113Lymphoma, Large B-Cell, Diffuse 105Sarcoma 102Lymphoma, Follicular 100

Interventions

Taxes 2Losartan 2Gemcitabine 2Albumin-Bound Paclitaxel 2durvalumab 1dehydroftorafur 1X-Rays 1Specimen Handling 1Radiotherapy 1Radiation 1Oxaliplatin 1Metformin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Pancreatic Adenocarcinoma × Clear all
NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03245541 2025-10-07

Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04986930 2025-01-28

SABER

Asan Medical Center

Phase 2 Active not recruiting
92 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡